Clinical Trials
Dato-DXd w/or w/o Durvalumab vs. Investigator's choice in patients with PDL1+ Triple Negative Breast Cancer
Disease Type: Breast
A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) with or without Durvalumab compared with Investigator's Choice of Chemotherapy (Paclitaxel/Nab-paclitaxel or Gemcitabine+ Carboplatin) in combination with Pembrolizumab in Patients with PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPIONBreast05)(D7630C00001)
Locations
Alleghany , Blacksburg , Roanoke , Salem , Wytheville